Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Corticosteroids for Children With Febrile Urinary Tract Infections (STARRS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Nader Shaikh, University of Pittsburgh Identifier:
First received: July 8, 2011
Last updated: December 1, 2016
Last verified: December 2016
In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.

Condition Intervention Phase
Acute Urinary Tract Infection
Urinary Tract Infection
Drug: Placebo
Drug: Dexamethasone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Corticosteroids for Children With Febrile Urinary Tract Infections

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • The proportion of children who have any renal scars on the outcome DMSA scan [ Time Frame: 6 months after the index UTI if no reinfection during the study period or 4 months after the last reinfection reinfection. ]

Secondary Outcome Measures:
  • The proportion of children with grades 3 or 4 scarring on at least one kidney (as defined in the study protocol). [ Time Frame: Same as for primary outcome ]

Estimated Enrollment: 390
Study Start Date: September 2011
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Adjuvant dexamethasone Drug: Dexamethasone
0.15 mg/kg/dose twice daily for 3 days
Other Names:
  • Prelone
  • Orapred
  • Corticosteroid
Placebo Comparator: Placebo Drug: Placebo
Twice daily for 3 days
Other Name: Inactive medicine

Detailed Description:
Because host inflammatory response is the final and most important step in the formation of renal scars, the use of anti-inflammatory agents may be the best strategy to reduce renal scarring. In animal studies, the use of corticosteroids has been shown to be effective in preventing post-pyelonephritic scarring. We will conduct a randomized, double-blind, placebo-controlled trial to determine the efficacy of 3 days of daily adjuvant dexamethasone on the incidence of renal scarring 4 to 6 months after a first febrile UTI. We hypothesize that the proportion of children with UTI who develop renal scarring will be lower among children who are treated with both dexamethasone and antibiotics as compared with children treated with antibiotics alone.

Ages Eligible for Study:   2 Months to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 2 months to 6 years
  • Pyuria (≥10 WBC/mm3 in an uncentrifuged specimen or ≥5 WBC/hpf in a centrifuged specimen or ≥1+ leukocyte esterase on dipstick)
  • Fever: documented temperature of at least 101 °F or 38.3°C, measured anywhere on the body either at home or at doctor's office within 24 hours of diagnosis

Exclusion Criteria:

  • Other concurrent systemic bacterial infection(s) such as meningitis or pneumonia;
  • Planned admission to intensive care unit;
  • Known bacteremia;
  • Previous protocol defined UTI;
  • Known major urinary tract anomalies (severe hydronephrosis, ureterocele, urethral valve, solitary or profoundly small kidney, multicystic dysplastic kidney, neurogenic bladder, pelvic or fused kidney);
  • Congenital/acquired immunodeficiency;
  • Bag urine collection
  • Chronic diseases that could potentially interfere with response to therapy, such as chronic gastrointestinal conditions (i.e. malabsorption, inflammatory bowel disease), liver/kidney failure;
  • Allergy to dexamethasone
  • Antibiotic use within 7 days of enrollment (except if given in the last 48 hours)
  • Systemic use of corticosteroids or other immunomodulating agents within 14 days of enrollment
  • History of Kawasaki disease
  • Sickle cell disease (not trait)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01391793

Contact: Nader Shaikh, MD 412-692-8111
Contact: Diana Kearney, CCRC 412-692-6717

United States, District of Columbia
Children's National Medical Center Active, not recruiting
Washington, District of Columbia, United States, 20010
United States, Ohio
Nationwide Children's Hospital in Columbus Active, not recruiting
Columbus, Ohio, United States, 43205
United States, Pennsylvania
Children's Hospital of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Principal Investigator: Nader Shaikh, MD         
Sub-Investigator: Alejandro Hoberman, MD         
United States, Rhode Island
Hasbro Children's Hospital Active, not recruiting
Providence, Rhode Island, United States, 02903
United States, Wisconsin
American Family Children's Hospital Recruiting
Madison, Wisconsin, United States, 53792
Principal Investigator: Ellen R Wald, MD         
Sponsors and Collaborators
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Nader Shaikh, MD University of Pittsburgh
  More Information

Responsible Party: Nader Shaikh, Assistant Professor of Pediatrics, University of Pittsburgh Identifier: NCT01391793     History of Changes
Other Study ID Numbers: R01DK087870 ( US NIH Grant/Contract Award Number )
Study First Received: July 8, 2011
Last Updated: December 1, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by University of Pittsburgh:
Renal scarring
Urinary tract infection
Escherichia Coli Urinary Tract Infection

Additional relevant MeSH terms:
Communicable Diseases
Urinary Tract Infections
Urologic Diseases
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017